BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7705108)

  • 1. The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia.
    Gallant JE; McAvinue SM; Moore RD; Bartlett JG; Stanton DL; Chaisson RE
    Chest; 1995 Apr; 107(4):1018-23. PubMed ID: 7705108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Pneumocystis carinii pneumonia: who are we missing?
    Schwarcz SK; Katz MH; Hirozawa A; Gurley J; Lemp GF
    AIDS; 1997 Aug; 11(10):1263-8. PubMed ID: 9256945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in hospital admissions pattern in patients with human immunodeficiency virus infection in the era of Pneumocystis carinii prophylaxis.
    Chien SM; Rawji M; Mintz S; Rachlis A; Chan CK
    Chest; 1992 Oct; 102(4):1035-9. PubMed ID: 1395739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
    Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
    N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
    Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
    Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics of Pneumocystis carinii pneumonia in HIV-infected and HIV-noninfected patients.
    Nicolau DP; Ross JW; Quintiliani R; Nightingale CH
    Pharmacoeconomics; 1996 Jul; 10(1):72-8. PubMed ID: 10160471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pneumocystis carinii pneumonia and HIV infection: diagnosis and treatment].
    González-García J; Rubio García R; Antela López A; García Alcaide F
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():36-44. PubMed ID: 9859618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1.
    Rigaud M; Pollack H; Leibovitz E; Kim M; Persaud D; Kaul A; Lawrence R; John DD; Borkowsky W; Krasinski K
    J Pediatr; 1994 Sep; 125(3):476-80. PubMed ID: 7915306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure.
    Wachter RM; Luce JM; Safrin S; Berrios DC; Charlebois E; Scitovsky AA
    JAMA; 1995 Jan; 273(3):230-5. PubMed ID: 7807663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
    Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
    Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of Pneumocystis Jiroveci Pneumonia Prophylaxis in HIV-Infected Patients.
    Lin X; Garg S; Mattson CL; Luo Q; Skarbinski J
    J Int Assoc Provid AIDS Care; 2016 Nov; 15(6):455-458. PubMed ID: 27629868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of morbidity and mortality in AIDS patients on Pneumocystis carinii prophylaxis who died during hospital admission: a report of 50 diseased patients.
    Hentzen BT; Schreij G
    Neth J Med; 1996 Sep; 49(3):101-5. PubMed ID: 8854672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era.
    Uphold CR; Deloria-Knoll M; Palella FJ; Parada JP; Chmiel JS; Phan L; Bennett CL
    Chest; 2004 Feb; 125(2):548-56. PubMed ID: 14769737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1995 Apr; 44(RR-4):1-11. PubMed ID: 7565543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumocystis pneumonia--a retrospective study 1991-2001 in Gothenburg, Sweden.
    Mikaelsson L; Jacobsson G; Andersson R
    J Infect; 2006 Oct; 53(4):260-5. PubMed ID: 16403575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure.
    Lundberg BE; Davidson AJ; Burman WJ
    AIDS; 2000 Nov; 14(16):2559-66. PubMed ID: 11101068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.